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Development and Validation of a Smartphone-Based
Visual Acuity Test (Peek Acuity) for Clinical Practice
and Community-Based Fieldwork
Andrew Bastawrous, MRCOphth; Hillary K. Rono, MBBS; Iain A. T. Livingstone, FRCOphth; Helen A. Weiss, PhD;
Stewart Jordan, BSc; Hannah Kuper, ScD; Matthew J. Burton, PhD
IMPORTANCE Visual acuity is the most frequently performedmeasure of visual function in
clinical practice andmost people worldwide living with visual impairment are living in low-
andmiddle-income countries.
OBJECTIVE To design and validate a smartphone-based visual acuity test that is not
dependent on familiarity with symbols or letters commonly used in the English language.
DESIGN, SETTING, AND PARTICIPANTS Validation study conducted fromDecember 11, 2013, to
March 4, 2014, comparing results from smartphone-based Peek Acuity to Snellen acuity
(clinical normal) charts and the Early Treatment Diabetic Retinopathy Study (ETDRS) logMAR
chart (reference standard). This study was nested within the 6-year follow-up of the Nakuru
Eye Disease Cohort in central Kenya and included 300 adults aged 55 years and older
recruited consecutively.
MAIN OUTCOMES ANDMEASURES Outcomemeasures weremonocular logMAR visual acuity
scores for each test: ETDRS chart logMAR, Snellen acuity, and Peek Acuity. Peek Acuity was
compared, in terms of test-retest variability andmeasurement time, with the Snellen acuity
and ETDRS logMAR charts in participants’ homes and temporary clinic settings in rural Kenya
in 2013 and 2014.
RESULTS The 95% CI limits for test-retest variability of smartphone acuity data were ±0.029
logMAR. Themean differences between the smartphone-based test and the ETDRS chart and
the smartphone-based test and Snellen acuity data were 0.07 (95% CI, 0.05-0.09) and 0.08
(95% CI, 0.06-0.10) logMAR, respectively, indicating that smartphone-based test acuities
agreed well with those of the ETDRS and Snellen charts. The agreement of Peek Acuity and
the ETDRS chart was greater than the Snellen chart with the ETDRS chart (95% CI, 0.05-0.10;
P = .08). The local Kenyan community health care workers readily accepted the Peek Acuity
smartphone test; it requiredminimal training and took no longer than the Snellen test (77
seconds vs 82 seconds; 95% CI, 71-84 seconds vs 73-91 seconds, respectively; P = .13).
CONCLUSIONS AND RELEVANCE The study demonstrated that the Peek Acuity smartphone
test is capable of accurate and repeatable acuity measurements consistent with published
data on the test-retest variability of acuities measured using 5-letter-per-line retroilluminated
logMAR charts.
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V isual acuity (VA) is themost frequentlyperformedmea-sureofvisual function in clinical practice.Visual acuitymeasurementsareusedtoestablish theneedforclinical
investigation andquantify changes in central visionover time.
Four percent of those who attend general practice in the
UnitedKingdomdosowithaneyeproblem1 anda formalmea-
sureofVAshouldbepart of eachof these consultations.2Glob-
ally, 285millionpeoplehavevisual impairment,with80%hav-
ing diseases with known curative or preventive treatment.
However,most live in low-incomecountrieswithminimal ac-
cess to detection and subsequent treatment.3
The Snellen chart4 is the most common method for the
measurement of VA in ophthalmic and general practice; how-
ever, it is limitedby thenongeometric progression in letter siz-
ing from line to line and the inconsistent number of letters per
line.5 Different letters or optotypes (standardized symbols for
testingvision) havevarying legibility at the same size and sec-
ondary effects, such as crowding, are known to affect the abil-
ity of the patient to determine optotypes correctly and there-
fore could lead to measurement bias.
The limitationsof theSnellencharthave largelybeenover-
comewith the development of logMAR acuity charts,6 which
are now frequently used in clinical research, such as theEarly
Treatment Diabetic Retinopathy Study (ETDRS) charts. De-
spite this improvement, the Snellen chart remains the domi-
nant method for acuity testing in clinical practice.7 This may
be owing to several factors including familiarity, a well-
recognized scoring system, smaller chart size, and the speed
of performing the test relative to the ETDRS chart test.
Mobile telephone technology has evolved rapidly in re-
cent years. In 2013, an estimated 280 million (20%) of the 1.4
billionmobile telephones soldwere smartphonesand thispro-
portion is expected to increase, particularly in low-income
settings,8 where fixed-line technology has been leapfrogged
straight to mobile technology,9 providing the potential to ac-
cesshealthcarewithoutthepreviouslyrequiredinfrastructure.10
The medical community is embracing mobile technolo-
gieswith its potential in health care informationdelivery, real-
time patient monitoring, research data collection, andmobile
telemedicinefortheprovisionofexpertisetoremotelocations.10
We hypothesized that a logMAR-style smartphone-based
vision test (PeekAcuity),with a fast-testing algorithm,would
allowmeasurements tobemade inaclinically acceptable time,
with greater precision and reliability than is possible with
Snellen charts. Visual acuity results canbedisplayed in famil-
iar Snellen chart notation (imperial or metric) or logMAR.
The Peek Acuity test was developed and compared, in
terms of test-retest variability (TRV) andmeasurement time,
with the Snellen chart and the ETDRS-based tumbling E
logMAR chart (reference standard) in controlled and uncon-
trolled (real-world) settings in rural Kenya.
Methods
Participants
This study, conducted from December 11, 2013, to March 4,
2014, was nested within the 6-year follow-up of the Nakuru
Eye Disease Cohort in central Kenya, a population-based
study that recruited 5000 individuals from 100 clusters in
2007 selected through probability proportionate to the size
of the clusters, with individuals sampled within clusters
through compact segment sampling.11,12 Follow-up of the
participants was undertaken in 2013 and 2014.12 Three hun-
dred consecutive participants from the final 21 survey clus-
ters who were undergoing reference measures of VA as part
of the cohort follow-up were invited to enroll into this addi-
tional study of alternative VA measures. A temporary mobile
eye clinic was set up in the center of each cluster. All partici-
pants examined in the study were aged 55 years and older.
Ethics Approval
The study adhered to the tenets of the Declaration of
Helsinki13 and was approved by the ethics committees of the
London School of Hygiene and Tropical Medicine and the
African Medical and Research Foundation, Kenya. Approval
was sought from administrative heads in each cluster, usu-
ally the village chief, who were given a copy of the consent
form to read and pass on to those in the village.
Informed consent was obtained from all participants.
The objectives of the study and examination process were
explained in the local dialect in the presence of a witness.
All participants gave written (or thumbprint) consent to par-
ticipate.
Peek Acuity Test
The Peek Acuity application was written in Android and, for
thepurposes of this study,wasusedonaGalaxy SIII GT-I9300
(SamsungC&TCorp) runningAndroid4.0.Theapplicationwas
directly installed onto the test devices. Screenbrightnesswas
set to 100% within the application and all other options de-
tailed here are built in.
Peek Acuity follows the standard ETDRS chart design
with a 5 × 5 grid optotype letter E displayed in 1 of 4 orienta-
tions (90°, 180°, 270°, and 0°). The participant points in the
direction they perceive the arms of the E to be pointing and
the tester uses the touch screen to swipe accordingly, trans-
lating the gestures from the patient. The tester is masked to
the presented optotype and is unaware whether the partici-
pant is providing the correct response. This method reduces
verbal or nonverbal clues, which may bias the result. Single
At a Glance
• Visual acuity is an important measure of visual function,
necessary for decisionmaking with ophthalmic patients. This
research aimed to develop and validate a smartphone-based
visual acuity application.
• Peek Acuity appeared to be comparable in repeatability and
speed with Snellen acuity.
• Peek Acuity appeared to be comparable with Early Treatment
Diabetic Retinopathy Study logMAR for measuring visual acuity.
• Peek Acuity appeared to be reliable for in-home and in-clinic
assessment of visual acuity.
• Accurate measures of visual acuity can be performed
by nonhealth care personnel using Peek Acuity.
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optotypes are shown to reduce confusion; however, a bound-
ing box is used to simulate the crowding effect of a standard
ETDRS chart using a crowding bar, with thickness equivalent
to the limb of the optotype, and spacing between optotype
and crowding bar equal to that of half the total optotype size.
This contour interaction format matches that used by the ref-
erence standard ETDRS chart. A stair-casing algorithm is used
to simulate clinical practice for time efficiency.
Peek Acuity offers standardized alternatives to count fin-
gers, hand movements, and light perception. For count fin-
gers, the application randomly presents between 1 and 4 bars
and a correct or incorrect response is recorded on screen. For
handmovement, a solidblackbox,half thewidthof thescreen,
moves backward and forward across the screen. For percep-
tionof light,PeekAcuityswitchesonthe telephone’sLEDflash-
light and the participant is asked to identify if andwhen they
see the light comeonandoff,with theoption to assess for per-
ception of projection direction. Test completion is indicated
by a sound and vibration alert.
Visual acuity results can be displayed in logMAR or met-
ric or imperial Snellen units based on user preference. An ad-
ditional option, SightSim, presents a live video feed with a
gaussian blur equivalent to the outcome of the vision test
(eFigure 1 in the Supplement),which is of value in sharing the
information with those not familiar with acuity scoring.
Visual AcuityMeasurement
PairedVAmeasuresweremade inboth theparticipant’s home
and in the central clinic on2 consecutivedays. For all tests, the
presenting acuity was measured, with habitual correction if
worn. Onday 1, a health careworkerwith basic eye care train-
ing and a fieldworkerwithout formal health care training vis-
ited participants in their homes. The participantswere tested
using (1) Peek Acuity (logMAR units) at 2 m and (2) a reduced
3-m tumbling E Snellen chart (Sussex Vision) inside or close
to the participant’s home (eFigure 2 in the Supplement). The
order of the test was determined randomly by coin toss. The
detailed testing procedures are described in the eAppendix in
the Supplement.
On day 2, the participants seen on day 1 were reassessed
in the cluster’s central clinic. The same personnel retested
the study participants using (1) Peek Acuity (logMAR units)
at 2 m and (2) a reduced 3-m tumbling E Snellen chart to
allow for measures of TRV. The order of the test was deter-
mined randomly by coin toss. The ETDRS VA was measured
using a back-illuminated 4-m ETDRS chart (Precision Vision
Inc) (eFigures 3 and 4 in the Supplement) by an ophthalmic
clinical officer, which is the reference standard for this
study. All testing (ETDRS, Snellen, and Peek Acuity) at the
different cluster clinic sites was standardized: conducted
indoors, the test area was screened with blackout curtains,
and there were controlled ambient light levels within a range
of 80 to 300 lux (ISO-TECH: ILM1332A light meter), in accor-
dance with British standards for acuity assessment.14
Statistical Analysis
In total, 8 comparisons of the various VAmeasures in the dif-
ferent settings were made (Figure 1).
For any pairwise comparison of methods, the TRV was
estimated as 95% CI limits of agreement (mean paired differ-
ence between measures ±1.96 SD). Histograms of the distri-
bution of the test-retest and between-test method variability
data suggested that the data were consistent with a normal
distribution. Scatterplots of the observed TRV plotted
against the average of the difference between the test and
retest measurements suggested that there were no system-
atic associations between TRV and the underlying bias relat-
ing to level of acuity. Therefore, the Bland and Altman15
methods were used for (1) bias (mean and 95% CI of the
mean) between ETDRS (reference test) and both Snellen and
Peek Acuity scores and (2) TRV for the paired Snellen acuity
and Peek Acuity scores. Mean time scores between Snellen
and Peek Acuity tests were compared using paired t tests.
Acuity scores were converted into a logMAR for data analy-
sis. In the Supplement, eTable 1 outlines the logMAR scores
used including where acuity was too poor to measure with
optoytypes.16
Results
The Peek Acuity study took place between December 2013
and March 2014. Of the 300 participants selected, 293
enrolled (98%; 135 men and 158 women). In total, 272 people
(91%; mean age, 65 years; range, 55-97) were examined and
completed all 3 tests in the central clinic on day 2. Of these,
233 (86%) were available and had also taken both VA tests at
home on day 1.
Figure 1. Testing Regimen of Peek Acuity, Snellen, and LogMAR
in the Participants’ Homes and in Clinics
Home Clinic
4
5
6
8
1
2
3
7
1 represents Early Treatment Diabetic Retinopathy Study (ETDRS) in the clinic
(reference standard) vs Snellen in the clinic; 2, ETDRS in the clinic vs Peek
Acuity in the clinic; 3, Snellen in the clinic (clinical norm) vs Peek Acuity in the
clinic; 4, Snellen at home vs Peek Acuity at home; 5, ETDRS in the clinic vs
Snellen at home; 6, Snellen at home vs Snellen in the clinic (test-retest
variability); 7, Peek Acuity at home vs Peek Acuity in the clinic (test-retest
variability); and 8, ETDRS in the clinic vs Peek Acuity at home.
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The median VAmeasured by the ETDRS chart for all eyes
tested (all levels of vision including those unable to read the
ETDRS chart) was 0.23 logMAR, with a range of −0.2 to 4.0
logMAR (Snellen equivalents: median, 20/32; range, 20/12.5
to no light perception).
The results of the 8 pairwise comparisons of the right
eye VA described here are presented in Table 1 and Figure 2,
with results for the left eye available in the eAppendix in the
Supplement (no difference between the right and left eyes
was found; eTable 2 in the Supplement). The comparisons
of clinic-based Snellen and clinic-based Peek Acuity mea-
sures with the ETDRS chart under the standardized clinic
conditions indicated that Snellen tests showed a high
degree of correlation with the ETDRS chart but that this was
higher still with Peek Acuity (95% CI, 0.05-0.10; P = .08).
The mean difference between the Peek Acuity measure in
the clinic and the ETDRS chart measure was 0.011 logMAR
units (95% CI, −0.014 to 0.035) and 0.032 logMAR units (95%
CI, 0.010 to 0.054) for the right and left eyes, respectively.
This was equivalent to less than 3 letters on a line difference
when taking the upper confidence limit of the mean differ-
ence. The correlation (scatter) plots and Bland-Altman dif-
ference plots for these comparisons in the right eye are
shown in Figure 3A.
Comparing Peek Acuity tested at home with ETDRS test-
ing in the clinic, the mean difference between the Peek Acu-
ity score athomeand theETDRSscorewas0.055 logMAR (95%
CI, 0.023-0.088) and 0.072 logMAR (95% CI, 0.039-0.105) for
the right and left eyes, respectively, which is equivalent to
5 letters or 1 line of difference (Table 1; Figure 3B).
ThePeekAcuityTRV(comparison7as indicated inFigure1)
performedby the sameexaminer onday 1 at homeandonday
2 in the clinic had a high correlation and a small difference of
averages (Table 1; Figure 3C).17
Mean testing time for both eyes on 126 study participants
in whom testing timewasmeasuredwas 82 seconds (95% CI,
73-91 seconds)withSnellen and77 seconds (95%CI, 71-84 sec-
onds) with Peek Acuity, showing no difference (P = .13).
Peek Acuity used at home by a community health care
worker was 85% sensitive and 98% specific (eTable 3 in the
Supplement) at detecting eyeswith severe visual impairment
(deemed locally as the surgical cutoff point for operable cata-
ract; Snellen equivalent of ≤6/60) when compared with the
ETDRS testing in controlled conditions. In addition, therewas
excellent agreement acrossWorldHealthOrganization vision
categoriesbetweenETDRSandPeekAcuitywhenusedathome
(eTable 4 in the Supplement).
No adverse events fromperforming anyof the acuity tests
were reported.
Table 1. Results of the 8 Pairwise Comparisons of the Right Eye Showing Bland-Altman and Pearson Correlation Analysis
Comparison
Participants,
No. Description
Difference
of Average
95% CI
Mean
Difference
95% Limits
of Agreement
Pearson
Correlation
Coefficient
(95% CI)
1 272 ETDRS vs Snellen in the clinic 0.088 0.063 to 0.114 −0.329 to 0.506 0.932
(0.914 to −0.946)
2 272 ETDRS vs Peek Acuity in the clinic 0.011 −0.014 to 0.035 −0.396 to 0.417 0.936
(0.919 to 0.949)
3 272 Snellen in the clinic vs Peek Acuity in the clinic −0.078 −0.100 to −0.056 −0.439 to 0.283 0.950
(0.937 to 0.960)
4 233 Peek Acuity at home vs Snellen at home 0.029 −0.007 to 0.065 −0.517 to 0.575 0.902
(0.875 to 0.923)
5 233 ETDRS vs Snellen at home 0.084 0.043 to 0.125 −0.541 to 0.709 0.865
(0.828 to 0.894)
6 233 Snellen in the clinic vs Snellen at home −0.004 −0.038 to 0.030 −0.523 to 0.515 0.907
(0.881 to 0.927)
7 233 Peek Acuity at home vs Peek Acuity in the clinic −0.054 −0.083 to −0.025 −0.498 to 0.390 0.933
(0.914 to 0.948)
8 233 ETDRS vs Peek Acuity at home 0.055 0.023 to 0.088 −0.438 to 0.549 0.917
(0.893 to 0.935)
Abbreviation: ETDRS, Early Treatment Diabetic Retinopathy Study.
Figure 2. Difference of the Average
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The graph shows 8 outcomes (right eye), with difference of the average in
logMAR on the y-axis and comparisons on the x-axis. 1 represents Early
Treatment Diabetic Retinopathy Study (ETDRS) in the clinic (reference
standard) vs Snellen in the clinic; 2, ETDRS in the clinic vs Peek Acuity in the
clinic; 3, Snellen in the clinic (clinical norm) vs Peek Acuity in the clinic;
4, Snellen at home vs Peek Acuity at home; 5, ETDRS in the clinic vs Snellen at
home; 6, Snellen at home vs Snellen in the clinic (test-retest variability);
7, Peek Acuity at home vs Peek Acuity in the clinic (test-retest variability);
and 8, ETDRS in the clinic vs Peek Acuity at home.
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Figure 3. Scatter and Bland and Altman Plots
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The scatter and Bland and Altman plots for outcomes 2, 8, and 7 for the right eye (RE).
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Discussion
Theubiquityofsmartphonesamonghealthcareprofessionals18
and increasing penetration, particularly in low- and middle-
income countries, provide potential for delivering high-
quality, objective, repeatable, and acceptable vision testing
throughout the world.
With most of the world’s blind people living in low-
income countries, the need for tools to increase early detec-
tion and appropriate referral are vital if the prevalence of
blindness and visual impairment is to be reduced. In high-
income settings, where primary care consultations are time
pressured and confidence in diagnosing ophthalmic prob-
lems is low,19 accessible tools to provide reliable measures to
guide management are vital. The referral of patients with
ophthalmic symptoms from primary care, such as in general
practice or accident and emergency, to specialist care should
include a measure of acuity that is reliable and accessible
and further testing in these contexts is encouraged.
In this study, we aimed to develop and validate a smart-
phone-based VA test appropriate for use in challenging cir-
cumstances, such as rural Africa, as well as being reliable
enough for use in routine clinical practice inwell-established
health care systems.Overall, PeekAcuity performedwell and
the testing timewasno slower or less repeatable thanwith the
Snellen test,while being comparable in accuracy to theETDRS
chart.Forclinicalandpopulationscreeninguse, theTRVofacu-
ity should be consistent across the acuity range and measur-
able in terms of lines or letters of change;measurement error
obscures true clinical changeand reduces the statistical power
of clinical trials using acuity as a primary outcomemeasure.20
PeekAcuity testingproved tobe repeatableandconsistent.Our
findings also indicated that the reduced Snellen chart is a re-
peatable and time-efficientVA test that still has application in
clinical and field settings.
In our study, theTRVof the Snellen chartwas higher than
incomparablestudies,5,21whichmayhavebeenowingtotightly
definedendpoints (nopart scoreswere given for part comple-
tion of a line).
Although multiple applications for the testing of VA on
smartphones are available, to our knowledge, most have not
been tested for repeatability or reliability against a reference
standard.22ThisstudyfoundPeekAcuity tobecomparablewith
ETDRS-style chart, with similar TRV to that previously re-
ported for other tests.23,24Key attributes andbenefits for Peek
Acuity are outlined in Table 2.
LowVision
Low vision in participants who have VA below the level that
can be measured on a chart are subject to assessment of
vision that lacks a standardized approach and is open to con-
siderable variability. In standard practice, if no optotypes are
visible at the reduced distance, counting fingers is per-
formed, followed by hand movements and finally differenti-
ating between perception of light and no perception of light.
In practice, this crucial measure of vision that may differen-
tiate poor and good prognosis for treatment is often over-
looked owing to these nonstandardized measures. Peek Acu-
ity offers a standardized approach to testing such low levels
of vision, which could be also performed on a tablet but was
not assessed formally in this study.
Limitations
The study population comprised older-aged Kenyan adults,
who may not be representative of other populations and age
groups, limiting the generalizability. Other studies are ongo-
ing to determine the suitability of this tool in different con-
texts across a range of different handsets and operating sys-
tems (this studyonlyassessed thedeviceonmultiplehandsets
of the same telephone model and operating system), includ-
ing a school-aged population. Reflection from smartphone
Table 2. Key Attributes and Potential Benefits of Peek Acuity
Key Attribute Potential Benefits
Use of E optotype widens accessibility
to those unable to read letters
Increased objectivity of test
Use of E optotype rather than letters
ensures acuity is resolution based
rather than recognition based
Random optotype direction prevents
learning effect from one eye
to the other
Automated visual acuity
score calculation
End-of-test indicator (vibration
and sound alert)
Gesture-based recording of responses,
making the test more objective
by swiping in the direction indicated
while not seeing the letter and shake
to record not seen
Standardized low-vision measurement
tools for count fingers, hand
movements, and perception of light
Standardized testing and
prompts for control
of conditions
Ambient light sensor used for adjusting
screen brightness and detecting
threshold ambient light levels above
which acuity measurements decrease
in accuracy
Use of ETDRS-based optotype with
result available in all the standard units:
decimal, logMAR, metric Snellen,
and imperial Snellen
Easy interpretation
of the results
Live video feed demonstrating
appropriate level of gaussian blur
according to outcome of the vision test
(eFigure 1 in the Supplement), which is
of value in sharing the information with
those not familiar with acuity scoring
Downloadable from the Google
Play Store
Accessible and validated
CE marked (class I)
Smartphone based Potential to store data to
an electronic patient record,
increasing efficiency of data
management and limiting
potential recording error
Data can be shared remotely
with other health care
professionals for feedback
The electronic patient record
can be geotagged, which is
of particular value in
resource-limited settings
where addresses may not be
available and patient follow-up
is challenging
Abbreviation: ETDRS, Early Treatment Diabetic Retinopathy Study.
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screens owing to bright sunlight can be problematic, al-
thoughantiglare screenshavebeen shown to reduce this limi-
tation on other platforms.25 Smartphones are on the whole
more expensive than a basic Snellen chart but less expensive
than a retroilluminated logMARor Snellen chart.With the in-
creasedavailabilityof low-cost smartphonesandtablets,many
health care workers may already own a device suitable for
downloading multiple applications.26
Concerns exist about data sharing and misuse with mo-
bile health platforms, which should be integrated with sys-
tems compliant with approved standards for data sharing.
Owing to the size,weight, andpower requirements, itwas
not possible to perform the ETDRS chart test in participants’
homes and, therefore, TRV of the ETDRS test was not as-
sessed as with the Snellen and Peek Acuity tests. Therefore,
we were unable to assess ETDRS TRV in this environment.
Nonhealthcareworkerswhoreceivedspecifictraininginhow
to use PeekAcuity performed the testing; further investigation
ofPeekAcuity’susabilitywithonlyinbuilt instructionsisrequired.
Testing Distance
During the early development phase, Peek Acuity was per-
formed at 3 m. However, in the study setting, it was often not
possible to find an indoor spaceof 3m to conveniently perform
the test. In conditionswhere the ambient lightmeasure on the
telephone was greater than 1000 lux, measures of Peek Acuity
did not correlate well with the reference standard. With a 4.8-
inch screen, 720 × 1280pixels, and a viewingdistance of 2m, it
ispossibletomeasureacuityof1.0 logMARand1.3 logMAR(Snel-
lenequivalentof20/200and20/400,respectively)whenthetest-
ing distance is reduced to 1 m. Therefore, the testing distance
and software algorithm were changed to 2 m. Following this
change, more than 90% of participants were tested indoors in
their homes. The smartphone’s inbuilt ambient light detector
(whichwasaccessedinthePeekAcuityapplicationtogiveamean
lux readingperVA test) provides awarning that test conditions
are not suitable if more than 1000 lux is detected.
Implications
Themorewidespread testingofVA in low- andmiddle-income
countries is likely to lead to greater awareness of treatable eye
diseasewithanincreaseduptakeofpreventiveandcurativetreat-
ments.Innonophthalmicdepartments,aneasilyaccessible,easy-
to-use, accurate, andreliablevision test could lead to increased
assessment of vision testing in routine practice.27
Conclusions
Additional applications to assess visual function and imaging
of the eyemake smartphones an attractive option for deliver-
ing ophthalmic assessment.28,29 In settings where ophthal-
mic instrumentationorophthalmic-trainedpersonnel are lim-
ited, the ability to reliablymeasure a change invisionordetect
abnormal vision, automation of stair-casing, masking of pre-
sented information, and generation of a jargon-free result
greatly improveefficacy in thehandsofminimally trainedper-
sonnel. The inherent connectivity and global positioning sys-
tem features of thedevicemayultimately lead tomorepeople
receiving timely and appropriate treatment.
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